搜索
Repligen Corp
RGEN添加自选
136.676USD
-0.324-0.24%
交易中 （美东）报价延迟15分钟
7.70B总市值
149.62市盈率 TTM
关于 Repligen Corp 公司
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Repligen Corp简介
公司代码RGEN
公司名称Repligen Corp
上市日期Apr 29, 1986
CEOLoeillot (Olivier)
员工数量1778
证券类型Ordinary Share
年结日Apr 29
公司地址Building 1, Suite 100
城市WALTHAM
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02453
电话17814499560
网址https://www.repligen.com/
公司代码RGEN
上市日期Apr 29, 1986
CEOLoeillot (Olivier)
Repligen Corp公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
Independent Director
Independent Director
--
--
Mr. James R. Bylund
Mr. James R. Bylund
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
常见问题
Repligen Corp的前五大股东是谁？
Repligen Corp 的前五大股东如下：Ms. Karen A. Dawes
有多少机构持有Repligen Corp(RGEN)的股份？
截至2026Q1，共有1067家机构持有Repligen Corp的股份，合计持有的股份价值约为65.93M，占公司总股份的116.89%。与2025Q4相比，机构持股有所增加，增幅为-2643397.00。
哪个业务部门对Repligen Corp的收入贡献最大？
在2026Q1，Product revenue - Filtration products业务部门对Repligen Corp的收入贡献最大，创收402.79M，占总收入的54.58%。
